Stanford, California 94305

  • Hypoglycemia


The purpose of this study is to evaluate the role of GLP-1 in causing extreme postprandial glucose reductions after bariatric surgery in a subset of patients who have severe symptomatic hypoglycemia.

Study summary:

The physiologic mechanisms mediating the glucose-lowering effect of Roux-en-Y Gastric Bypass (RYGB) or post-Vertical Sleeve Gastrectomy (VSG) are unknown. The reduction in glucose excursions prior to weight loss has lead to postulates that the incretin hormone, GLP-1, may play an important role. The purpose of this study is to evaluate the role of GLP-1 in causing extreme postprandial glucose reductions in a subset of post-bariatric patients through the pharmacologic blockade of the GLP-1 receptor in post-RYGB or post-VSG patients with severe symptomatic hypoglycemia.


Inclusion Criteria: - Men and women ages 18-65 - BMI 25-40 with a clinical diagnosis of severe symptomatic hypoglycemia after bariatric surgery Exclusion Criteria: - Acute medical illness, such as acute bacterial or viral syndrome, febrile illness, acute abdominal symptoms, orthopedic injury within one week - History of cardiac failure, renal insufficiency (estimated Crcl<30cc/min), hepatic insufficiency, chronic obstructive pulmonary disease, anemia (Hct<30%), or uncontrolled hypertension (SBP>160 or DBP>100) - Pregnancy - Use of medications that affect glucose metabolism - Fasting glucose >150 or HbA1c>7.5 on Metformin - Women of childbearing potential (will have a pregnancy test, in addition use of abstinence for at least one month prior to study or use two types of contraceptives, hormonal implant or Depo Provera) - Active, uncontrolled psychiatric disease - Participating in other studies or have received investigational medications within the past month or 5 half-lives of the drug, whichever is longer.



Primary Contact:

Study Director
Colleen Craig, M.D.
Stanford University

Colleen Craig, M.D.
Phone: 650-736-2056

Backup Contact:

Tracey McLaughlin, M.D.

Location Contact:

Stanford, California 94305
United States

Colleen Craig, M.D.
Phone: 650-350-2153

Site Status: Recruiting

Data Source:

Date Processed: September 27, 2021

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.